Developer docs
API playgroundTry for free, no card

Search company profiles

SMS-oncology

Full company profile

uuid000vtz2

Namestring
SMS-oncology
Legal namestring
Allucent
Company typeenum
Private
Founded yearint
1994
Descriptiontext

SMS-oncology is a full-service contract research organization (CRO) that specializes in oncology drug development, providing both clinical operations and expert advisory services to sponsors. Founded in 2007 and headquartered in Schiphol, Netherlands, the firm operates as a privately held company with a headcount in the 51-100 range, indicating a mid-sized specialist positioning rather than a top-tier full-service platform.

The company's core offering spans clinical development, clinical pharmacology, regulatory strategy, and drug safety and pharmacovigilance services. Operational infrastructure includes an internal clinical research site network (IGNITE) and structured Centers of Expertise that group capabilities around therapeutic areas such as oncology and hematology, infectious disease and vaccines, neuroscience, immunology and inflammation, cardiometabolic disease, cell and gene therapy, and rare diseases. Scale commentary in the source dataset attributes 1,090+ clinical trials, 70+ country reach, 12 former regulators on staff, and 825+ annual regulatory submissions to the CRO platform associated with the firm.

Revenue is generated through professional-services engagements priced on a quote basis against defined study scope, marketed via a sales-led motion targeting small and mid-sized biotech sponsors. Distribution runs through direct consultation and proposal requests via the company website, supported by content marketing, podcasts, webinars, whitepapers, and event participation. Pricing is not publicly disclosed and no anchor customer logos are named in the available data.

Short descriptiontext

SMS-oncology is a Netherlands-based, full-service contract research organization that provides clinical operations and expert advisory services for oncology drug development to small and mid-sized biotech sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSchiphol, Netherlands
HQ citystring
Schiphol
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology clinical research, CRO services, oncology drug development, clinical trial management, biotech advisory services
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code3 codes
  • Services-Health Services8000
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Full-service contract research organization (CRO) providing clinical development, clinical pharmacology, regulatory strategy, and drug safety services to small and mid-sized biotech companies throughout all phases of drug development from early-stage to post-approval.

allucent.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Allucent Centers of Expertise (ACEs)
Description

Designed, structured, and resourced to deliver comprehensive trial and regulatory strategy; effective patient-focused recruitment plans; and solutions meeting specific needs.

allucent.com
+2 more records
Core offering1 text field

SMS-oncology is a full-service oncology CRO that delivers clinical operations together with senior-level expert advice on oncology drug development. The company runs and supports clinical trials for oncology sponsors and provides strategic consulting on development plans, regulatory pathways, and program decisions for innovative oncology therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1,090+ clinical trials conducted
+3 more records
Product overview1 text field

Allucent is a global, full-service Contract Research Organization (CRO) partnering with small and mid-sized biotech and biopharma companies. The company operates as a unified service platform rather than a software product, offering integrated clinical research services across the drug development lifecycle from discovery through post-marketing approval. Core service offerings include Clinical Development Services (encompassing study start-up, IGNITE Site Network, patient recruitment, data management, biostatistics, and medical monitoring), Clinical Pharmacology Services (including PK/PD, First-in-Human studies, PopPK, and modeling/simulation), Regulatory Strategy (IND/NDA submissions, orphan drug designation, pediatric investigation plans, GxP consulting), Drug Safety & Pharmacovigilance, and Government & Public Health Services. These services are delivered through Allucent Centers of Expertise (ACEs) structured around therapeutic areas including Oncology & Hematology, Immunology & Inflammation, Neuroscience, Cell & Gene Therapy, Cardiometabolic Disease, Rare Disease, and Infectious Disease & Vaccine.

Product and service2 records
1Oncology Clinical Operations
CategoryClinical Operations
Description

Full-service clinical operations for oncology trials, providing execution support for biotech and biopharma sponsors conducting oncology drug development.

2Oncology Drug Development Advisory
CategoryDrug Development Consulting
Description

Expert consultancy and strategic advice on oncology drug development, providing senior-level guidance on development programs and regulatory pathways to small and mid-sized biotech sponsors.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medpace is a mid-size, full-service CRO with a strong oncology franchise serving small and mid-sized biotech sponsors. Directly comparable business model and customer segment, though at significantly greater scale than SMS-oncology.

TypeBroad incumbent
Description

ICON is a top-tier global CRO with comprehensive oncology capabilities after multiple acquisitions. Comparable in service breadth to SMS-oncology but operates at vastly greater scale across all major therapeutic areas.

TypeBroad incumbent
Description

Parexel is a large global CRO with a sizable oncology practice. Overlaps with SMS-oncology on oncology clinical operations but operates at significantly greater scale and across many additional therapeutic areas.

TypeDirect peer
Description

Allucent is a full-service CRO with strong oncology, neuroscience, and infectious disease focus serving small and mid-sized biotech sponsors. Highly comparable to SMS-oncology in target customer (small/mid-cap biotech), therapeutic emphasis on oncology, and integrated clinical + advisory offering.

TypeDirect peer
Description

Precision for Medicine is a CRO purpose-built around oncology and rare disease with biomarker and translational science capabilities. Comparable to SMS-oncology in oncology specialization, biotech sponsor focus, and integration of clinical operations with scientific advisory.

TypeBroad incumbent
Description

Fortrea, spun out from Labcorp, is a large CRO with broad oncology capability and central laboratory services. Comparable to SMS-oncology on the clinical operations side, with much broader scale and ancillary lab infrastructure.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with the most extensive oncology operational footprint. Direct overlap with SMS-oncology on oncology clinical services but at a fundamentally different scale, geographic reach, and technology stack.

TypeDirect peer
Description

Clinipace is a mid-size, therapeutically-focused CRO with notable oncology and rare disease expertise serving small and mid-sized biotech. Comparable in business model, therapeutic mix, and target customer to SMS-oncology.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-size CRO with therapeutic depth in oncology, neuroscience, and rare disease serving biotech and mid-cap pharma. Comparable to SMS-oncology in therapeutic specialization and biotech sponsor focus.

TypeDirect peer
Description

Novella was a boutique oncology-focused CRO serving small biotech sponsors — virtually the same niche as SMS-oncology — before being acquired by IQVIA. Serves as a useful prior-art comparator for the specialist oncology CRO model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SMS-oncology

Oncology Contract Research Servicessms-oncology.com

SMS-oncology is a Netherlands-based, full-service contract research organization that provides clinical operations and expert advisory services for oncology drug development to small and mid-sized biotech sponsors.

What SMS-oncology does

SMS-oncology is a full-service contract research organization (CRO) that specializes in oncology drug development, providing both clinical operations and expert advisory services to sponsors. Founded in 2007 and headquartered in Schiphol, Netherlands, the firm operates as a privately held company with a headcount in the 51-100 range, indicating a mid-sized specialist positioning rather than a top-tier full-service platform.

The company's core offering spans clinical development, clinical pharmacology, regulatory strategy, and drug safety and pharmacovigilance services. Operational infrastructure includes an internal clinical research site network (IGNITE) and structured Centers of Expertise that group capabilities around therapeutic areas such as oncology and hematology, infectious disease and vaccines, neuroscience, immunology and inflammation, cardiometabolic disease, cell and gene therapy, and rare diseases. Scale commentary in the source dataset attributes 1,090+ clinical trials, 70+ country reach, 12 former regulators on staff, and 825+ annual regulatory submissions to the CRO platform associated with the firm.

Revenue is generated through professional-services engagements priced on a quote basis against defined study scope, marketed via a sales-led motion targeting small and mid-sized biotech sponsors. Distribution runs through direct consultation and proposal requests via the company website, supported by content marketing, podcasts, webinars, whitepapers, and event participation. Pricing is not publicly disclosed and no anchor customer logos are named in the available data.

SMS-oncology firmographics

Firmographics
Name
SMS-oncology
Legal name
Allucent
Website
https://sms-oncology.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
51–100 employees
Short description
SMS-oncology is a Netherlands-based, full-service contract research organization that provides clinical operations and expert advisory services for oncology drug development to small and mid-sized biotech sponsors.
Ownership category
akta.pro rank

SMS-oncology industry classification

Industry
Product category
Oncology Contract Research Services
NAICS
Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Health Services (8000), Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology

Keywords

  • Oncology clinical research
  • CRO services
  • Oncology drug development
  • Clinical trial management
  • Biotech advisory services

Where SMS-oncology is headquartered

Location

Headquarters

HQ city
Schiphol
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

SMS-oncology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: Full-service contract research organization (CRO) providing clinical development, clinical pharmacology, regulatory strategy, and drug safety services to small and mid-sized biotech companies throughout all phases of drug development from early-stage to post-approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

SMS-oncology product offering

Product offering

Core offering

SMS-oncology is a full-service oncology CRO that delivers clinical operations together with senior-level expert advice on oncology drug development. The company runs and supports clinical trials for oncology sponsors and provides strategic consulting on development plans, regulatory pathways, and program decisions for innovative oncology therapies.

Product overview

Allucent is a global, full-service Contract Research Organization (CRO) partnering with small and mid-sized biotech and biopharma companies. The company operates as a unified service platform rather than a software product, offering integrated clinical research services across the drug development lifecycle from discovery through post-marketing approval. Core service offerings include Clinical Development Services (encompassing study start-up, IGNITE Site Network, patient recruitment, data management, biostatistics, and medical monitoring), Clinical Pharmacology Services (including PK/PD, First-in-Human studies, PopPK, and modeling/simulation), Regulatory Strategy (IND/NDA submissions, orphan drug designation, pediatric investigation plans, GxP consulting), Drug Safety & Pharmacovigilance, and Government & Public Health Services. These services are delivered through Allucent Centers of Expertise (ACEs) structured around therapeutic areas including Oncology & Hematology, Immunology & Inflammation, Neuroscience, Cell & Gene Therapy, Cardiometabolic Disease, Rare Disease, and Infectious Disease & Vaccine.

Differentiator

Problem solved

Functional benefit

Brands

  • Allucent Centers of Expertise (ACEs): Designed, structured, and resourced to deliver comprehensive trial and regulatory strategy; effective patient-focused recruitment plans; and solutions meeting specific needs.
  • IGNITE Site Network
  • Allucent Consulting

Products and services

  • Oncology Clinical Operations Full-service clinical operations for oncology trials, providing execution support for biotech and biopharma sponsors conducting oncology drug development.
  • Oncology Drug Development Advisory Expert consultancy and strategic advice on oncology drug development, providing senior-level guidance on development programs and regulatory pathways to small and mid-sized biotech sponsors.

Quantifiable outcome

  • 1,090+ clinical trials conducted
  • +3 more outcomes

Companies that use SMS-oncology

Customer profile

Segments1 record

Ideal customer profiles1 record

SMS-oncology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

SMS-oncology partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves5 records

Expansion highlights5 records

SMS-oncology competitors and assessment

Company assessment

Direct peers

  • Medpace: Medpace is a mid-size, full-service CRO with a strong oncology franchise serving small and mid-sized biotech sponsors. Directly comparable business model and customer segment, though at significantly greater scale than SMS-oncology.
  • Allucent: Allucent is a full-service CRO with strong oncology, neuroscience, and infectious disease focus serving small and mid-sized biotech sponsors. Highly comparable to SMS-oncology in target customer (small/mid-cap biotech), therapeutic emphasis on oncology, and integrated clinical + advisory offering.
  • Precision for Medicine: Precision for Medicine is a CRO purpose-built around oncology and rare disease with biomarker and translational science capabilities. Comparable to SMS-oncology in oncology specialization, biotech sponsor focus, and integration of clinical operations with scientific advisory.
  • Clinipace Worldwide: Clinipace is a mid-size, therapeutically-focused CRO with notable oncology and rare disease expertise serving small and mid-sized biotech. Comparable in business model, therapeutic mix, and target customer to SMS-oncology.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with therapeutic depth in oncology, neuroscience, and rare disease serving biotech and mid-cap pharma. Comparable to SMS-oncology in therapeutic specialization and biotech sponsor focus.
  • Novella Clinical (IQVIA): Novella was a boutique oncology-focused CRO serving small biotech sponsors — virtually the same niche as SMS-oncology — before being acquired by IQVIA. Serves as a useful prior-art comparator for the specialist oncology CRO model.

Broad incumbents

  • ICON plc: ICON is a top-tier global CRO with comprehensive oncology capabilities after multiple acquisitions. Comparable in service breadth to SMS-oncology but operates at vastly greater scale across all major therapeutic areas.
  • Parexel: Parexel is a large global CRO with a sizable oncology practice. Overlaps with SMS-oncology on oncology clinical operations but operates at significantly greater scale and across many additional therapeutic areas.
  • Labcorp Drug Development (Fortrea): Fortrea, spun out from Labcorp, is a large CRO with broad oncology capability and central laboratory services. Comparable to SMS-oncology on the clinical operations side, with much broader scale and ancillary lab infrastructure.
  • IQVIA: IQVIA is the world's largest CRO with the most extensive oncology operational footprint. Direct overlap with SMS-oncology on oncology clinical services but at a fundamentally different scale, geographic reach, and technology stack.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

SMS-oncology social profiles

Digital presence

SMS-oncology compliance and trust

Trust signal

Compliance2 records

SMS-oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SMS-oncology leadership team

Management profile

Number of profiles

SMS-oncology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SMS-oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SMS-oncology

What does SMS-oncology do?

SMS-oncology is a full-service oncology CRO that delivers clinical operations together with senior-level expert advice on oncology drug development. The company runs and supports clinical trials for oncology sponsors and provides strategic consulting on development plans, regulatory pathways, and program decisions for innovative oncology therapies.

Is SMS-oncology a public or private company?

SMS-oncology is a private company. It is classified as unknown and is currently operating.

When was SMS-oncology founded?

SMS-oncology was founded in 1994. It employs 51 to 100 people.

Where is SMS-oncology based?

SMS-oncology is headquartered in Schiphol, Netherlands, in the Europe region.

How does SMS-oncology make money?

One revenue line is on record: clinical Research Services.

Who are SMS-oncology's main competitors?

Direct peers on record are Medpace, Allucent, Precision for Medicine, Clinipace Worldwide, Worldwide Clinical Trials and Novella Clinical (IQVIA). Broad incumbents are ICON plc, Parexel, Labcorp Drug Development (Fortrea) and IQVIA.

Does SMS-oncology have an API?

No public API is recorded for SMS-oncology.

What industry is SMS-oncology in?

SMS-oncology's product category is Oncology Contract Research Services. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 54169 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCato Research ohlasuje fúziu so spoločnosťou SMS-oncologyCato Research announced a merger with SMS-oncology to expand its global pharmaceutical development support services, with the combined entity to be renamed CATO SMS next year. The deal aims to strengthen CATO's oncology portfolio, expand presence across Europe and North America, and deepen expertise in regulatory services. The merger follows last year's strategic investment by Water Street Healthcare Partners and JLL Partners, with financial terms undisclosed.PR NewswireCato Research Announces Merger With SMS-oncologyCato Research, LLC announced a merger with Specialized Medical Services-oncology BV (SMS-oncology) to form a combined company under the new name CATO SMS, pending transition over the coming year. The merger expands the combined entity's presence across Europe and North America, deepens oncology and regulatory expertise, and broadens services for small and mid-sized biotech and pharmaceutical companies. Dr. Mark A. Goldberg will serve as executive chairman while Philine van den Tol and the SMS-oncology management team will continue to lead operations.PR NewswireSpolečnost Cato Research oznámila fúzi se společností SMS-oncologyCato Research, LLC announced a merger with Specialized Medical Services-oncology BV (SMS-oncology) to strengthen its global drug development solutions portfolio, with the combined entity to be renamed CATO SMS in 2021. The deal expands both companies' presence in Europe and North America, deepens oncology and regulatory expertise, and brings together SMS-oncology's specialized CRO capabilities with Cato Research's regulatory services. SMS-oncology, headquartered near Schiphol Airport in the Netherlands, will continue to be led by CEO Philine van den Tol while Dr. Mark A. Goldberg serves as executive chairman of the merged company.PR NewswireCato Research kündigt Fusion mit SMS-oncology anCato Research (CATO) announced its merger with Specialized Medical Services-oncology BV (SMS-oncology) to strengthen its global portfolio of drug development solutions for life science organizations. The combined entity, which will be renamed CATO SMS next year, will deepen oncology and regulatory expertise while expanding presence across Europe and North America, with SMS-oncology's nearly 100 employees joining CATO's existing 200-person team. The companies will continue operating under their current brands until the full transition, with management from both organizations staying in place and financial terms remaining undisclosed.PR NewswireCato Research сообщила о слиянии с SMS-oncologyCato Research, LLC announced a merger with Specialized Medical Services-oncology BV (SMS-oncology), with the combined entity slated to be renamed CATO SMS in 2020. The deal expands the companies' global solutions for pharmaceutical and biotech clients by strengthening their presence in Europe and North America, deepening oncology and regulatory compliance expertise, and broadening their service portfolio. Financial terms of the transaction were not disclosed.PR NewswireCato Research annonce sa fusion avec SMS-oncologyCato Research, LLC (based in North Carolina) has merged with SMS-oncology BV (based in the Netherlands) to form CATO SMS, combining their pharmaceutical development services and expanding their oncology expertise and geographic presence in Europe and North America. The combined entity will be led by Dr. Mark A. Goldberg as executive chairman and Philine van den Tol as CEO, with the new branding to be adopted over the coming year. This merger follows Water Street Healthcare Partners and JLL Partners' investment in Cato Research last year and positions the expanded company to better serve small and medium pharmaceutical and biotech clients in complex therapeutic areas including oncology, gene and cell therapy, and rare diseases.news.cision.comDouble Bond Pharmaceutical joins hands with SMS-oncology for clinical development of SI-053Double Bond Pharmaceutical and SMS-oncology signed a consultancy agreement to support the clinical development of SI-053, a temozolomide formulation for glioblastoma. The company plans a European phase I trial with a first-patient-in milestone by end of 2020. The drug has received orphan drug designation from the EMA.PR NewswireCytovation and SMS-oncology Sign Agreement on Conduct of Phase I/II Trial With CyPep-1 in Solid TumorsCytovation AS and SMS-oncology have signed an agreement appointing the latter as the contract research organization to conduct a phase I/II clinical trial for CyPep-1 in patients with advanced solid cancers. The multicenter trial, planned to commence in Q4 2019 across Europe, will enroll approximately 18 patients to evaluate the safety and efficacy of the intratumoral injection. This development marks Cytovation's progression toward its first patient milestone for the first-in-class lytic agent.